Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: Effect of protein-binding differences on steady-state pharmacokinetics

Journal of Clinical Pharmacology

Volumn 37, Issue 4, 1997, Pages 267-278

  Karim, Aziz ^a   Noveck, Robert ^b   McMahon, F Gilbert ^b   Smith, Margo ^a   Crosby, Sharon ^a   Adams, Marijke ^a,c   Wilton, John ^d  

^a PFIZER INC   (United States)

^b General Clinical Research Center New Orleans   (United States)

^c Kos Pharmaceuticals   (United States)

^d Clinical Pharmacokinetics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXYGENASE; PIROXICAM; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PHARMACOKINETICS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0030891896     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04302.x     Document Type: Article

References (49)

1. Todesco S: Special considerations in the use of NSAIDs in the elderly. Eur J Rheumatol Inflamm 1994; 14:7-13.
2. Belcom MC, Haynes RB, Tugwell P: Critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum 1984; 27:1227-1230.
3. Woodhouse KW, Wynne H: Pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet 1987; 12:111-122.
4. Verbeeck RK: Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; 15(suppl):44-57.
5. Woodhouse KW, Wynne HA: Age-related changes in liver and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15:287-294.
6. Durnas C, Loi C-M, Cusack BJ: Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-389.
7. Hughes GR: The problems of using NSAIDs in the elderly. Scan J Rheumatol 1991; 20(suppl):19-25.
8. Wilson K: Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984; 9:189-202.
9. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-239.
10. Skeith KJ, Brocks DR: Pharmacokinetic optimization of the treatment of osteoarthritis. Clin Pharmacokinet 1994; 26:233-242.
11. Todd PA, Brogden RN: Oxaprozin: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986; 32:291-312.
12. Greenblatt DJ, Scavone JM: Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. Semin Arthritis Rheum 1986; 15(suppl):18-26.
13. Chiang ST, Morrison G, Knowles JA, Ruelius HW, Walker BR: Oxaprozin disposition in renal disease. Clin Pharmacol Ther 1982; 31:509-515.
14. Homon CA, Fluck ER, Janssen FW, Ruelius HW: Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent. Agents Actions 1982; 12:211-215.
15. Chiang ST, Lasseter KC, Fluck ER, Janssen FW, Leelavathi D, Hubsher JA: Oxaprozin dose proportionality. J Clin Pharmacol 1984; 24:515-522.
16. Miller LG: Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Clin Pharm 1992; 11:591-603.
17. Wiseman EH, Boyle JA: Piroxicam (Feldene): Anti-rheumatic drugs II. Clin Rheum Dis 1980; 6:585-613.
18. Brogden RN, Heel RC, Speight TM, Avery GS: Piroxicam, a reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28:292-323.
19. Verbeeck RK, Richardson CJ, Blocka KL: Clinical pharmacokinetics of piroxicam. J Rheumatol 1986; 13:789-796.
20. Chiang ST, Knowles JA, Hubsher JA, Ruelius HW, Walker BR: Effects of food on oxaprozin bioavailability. J Clin Pharmacol 1984; 24:381-385.
21. Ishizaki T, Nomura T, Abe T: Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm 1979; 7:369-381.
22. Twomey TM, Hobbs DC: Biotransformation of piroxicam by man. Fed Proc 1978; 37:271.
23. Woolf TF, Radulovic LL: Oxicams: metabolic disposition in man and animals. Drug Met Rev 1989; 21:255-276.
24. Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW: Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharmacol Ther 1980; 27:352-362.
25. Verbeeck RK, Wallace SM: Non-steroidal anti-inflammatory drugs: Restrictive or non-restrictive hepatic clearance? Arzneim-Forsch/Drug Res 1994; 44:683-685.
26. Wanwimolruk S, Birkett DJ, Brooks PM: Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet 1982; 7:85-92.
27. Lin JH, Cocchetto DM, Duggan DE: Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987; 12:402-432.
28. Tozer TN: Concepts basic to pharmacokinetics. Pharmacol Ther 1981; 12:109-131.
29. McNamara PJ, Gibaldi M, Stoeckel K: Volume of distribution terms for a drug (Ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur J Clin Pharmacol 1983; 25:399-405.
30. Ludden TM: Nonlinear pharmacokinetics. Clinical implications. Clin Pharmacokinet 1991; 20:429-446.
31. Wright JD, Boudinot FD, Ujhelyi MR: Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996; 30:445-462.
32. Kupfer A, Schmid B, Preisig R, Pfaf G: Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 2:517-518.
33. Guttendorf RJ, Wedlund PJ, Blake J, Chang SL: Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism. Ther Drug Monit 1988; 10:490-498.
34. Schmid B, Bircher J, Presig R, Kuepfer A: Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
35. McHugh SL, Kirman SK, Knowles JA: Macro and micro method for high performance liquid chromatographic analysis of oxaprozin in plasma. J Pharm Sci 1980; 69:794-796.
36. Boudinot FD, Ibrahim SS: High performance liquid chromatographic assay for piroxicam in human plasma. J Chromat 1988; 430:424-428.
37. Gillilan RB, Mason WD, Joky Fu CH: Rapid analysis of piroxicam in dog, rat and human plasma by high-performance liquid chromatography. J Chromat 1989; 487:232-235.
38. Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK: Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 1987; 32:89-91.
39. Hejmanowski LG, Keem RF, Adams MH, Longstreth J, Wilton JH: Determination of free oxaprozin (OXA) plasma concentrations by ultrafiltration (abstract). Pharm Res 1993; 10:S46.
40. Blocka KLN, Richardson CJ, Wallace SM, Ross SG, Verbeeck RK: The effect of age on piroxicam disposition in rheumatoid arthritis. J Rheum 1988; 15:757-763.
41. Karim A: Inverse nonlinear pharmacokinetics of total and protein unbound drug oxaprozin: clinical and pharmacokinetic implications. J Clin Pharmacol 1996; 36:985-997.
42. Graham GG: Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs. Med J Austr 1987; 147:597-602.
43. Brooks PM, Day RO: Nonsteroidal anti-inflammatory drugs -differences and similarities. New Engl J Med 1991; 324:1716-1725.
44. Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI: Oxaprozin pharmacokinetics in the elderly. Br J Clin Pharmacol 1985; 19:373-378.
45. Zinny MA: Effects of age and sex on oxaprozin single-and multiple-dose pharmacokinetics. Drug Therapy 1993; 23(suppl):37-45.
46. Leemann TD, Transon C, Bonnabry P, Dayer P: A major role of cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drug Exptl Clin Res 1993; 19:189-195.
47. Zhao J, Leemann T, Dayer P: In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 1992; 51:575-581.
48. Leemann T, Transon C, Dayer P: Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 1993; 52:29-34.
49. Transon C, Leemann T, Vogt N, Dayer P: In-vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995; 58:412-417.